Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

429.54 +3.10 (+0.73%)
Streaming Delayed Price Updated: 12:33 PM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Value Investment Case Study
Vertex Pharmaceuticals (VRTX) presents a value investing case with strong profitability, a debt-free balance sheet, and a valuation that appears attractive relative to its industry peers. 
Via Chartmill
2 Growth Stocks to Invest $1,000 in Right Now
These companies have a habit of beating the market, and they are far from having peaked. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
From Vertex Pharmaceuticals Incorporated
Via Business Wire
2 Soaring Cathie Wood Stocks to Buy and Hold
These companies' market-beating fuel hasn't run out yet. 
Via The Motley Fool
Vera Therapeutics' Lead Kidney Drug Poised For 2026 Launch In Multi-Billion-Dollar Market
Bank of America initiates coverage on Vera Therapeutics, citing strong potential for atacicept, its kidney treatment. 
Via Benzinga
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Offers Affordable Growth in Biotech
Vertex Pharmaceuticals (VRTX) offers strong growth, solid earnings, and a robust financial position, all at a reasonable price compared to biotech peers. 
Via Chartmill
2 Unstoppable Growth Stocks to Buy During a Market Crash
Here are two smart ways to prepare for the next market downturn. 
Via The Motley Fool
Topics Government Stocks World Trade
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
 
Via Benzinga
4 Healthcare Stocks to Buy Now
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations. 
Via The Motley Fool
Topics Artificial Intelligence
Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity
 
Via Benzinga
The Smartest Growth Stock to Buy With $500 Right Now
Vertex isn't your run-of-the-mill biotech stock. 
Via The Motley Fool
Topics Economy
Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?
Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This... 
Via StockStory
Topics Stocks
Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500
Tariffs aren't likely to weigh on growth at these companies. 
Via The Motley Fool
Topics Government Stocks World Trade
Vertex to Announce Third Quarter 2025 Financial Results on November 3rd
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
 
Via Benzinga
1 Healthcare Stock with Exciting Potential and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
2 Beaten-Down Stocks Primed for a Comeback
The market is sleeping on these stocks, but you don't have to. 
Via The Motley Fool
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'
Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX). 
Via Benzinga
Topics ETFs Stocks
Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented... 
Via TokenRing AI
Topics Artificial Intelligence
Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data
New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
What Does the Market Think About Vertex Pharmaceuticals Inc?
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
2 S&P 500 Stocks to Research Further and 1 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
5 Top Stocks to Buy in October
These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term. 
Via The Motley Fool
Topics Stocks
Pharma Tariffs Back In Spotlight On New Trump Threat
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.